Mucoepidermoid carcinoma of salivary glands in the pediatric age group: 18 clinical cases, including 11 second malignant neoplasms

Head Neck. 2006 Sep;28(9):827-33. doi: 10.1002/hed.20429.

Abstract

Background: Salivary gland tumors represent 1% of head and neck tumors, with only 5% of these occurring in patients younger than 20 years. Mucoepidermoid carcinoma (MEC) is one of the most frequent salivary gland cancers among adults and children.

Methods: This survey was conducted among 34 French pediatric oncology departments. From 1980 to 2000, 18 cases were reported.

Results: Treatment included surgery or radiotherapy, or both. The 5-year survival rate was 93.7%. Eleven patients had been previously treated by radiotherapy and/or chemotherapy for a first malignant tumor, specifically, lymphoid leukemia (n = 4), lymphoma (n = 3), brain tumor (n = 2), sarcoma (n = 1), and retinoblastoma (n = 1).

Conclusions: MEC is very rare in the pediatric age group. Treatment involves surgical removal of the tumor plus radiotherapy, according to histologic staging. MEC has a good prognosis in young patients. The survival rate does not differ in the subgroup of patients with MEC as a secondary tumor.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Carcinoma, Mucoepidermoid / pathology*
  • Carcinoma, Mucoepidermoid / secondary
  • Carcinoma, Mucoepidermoid / therapy
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Lymphoma / pathology
  • Male
  • Neoplasms, Neuroepithelial / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Rhabdomyosarcoma / pathology
  • Salivary Gland Neoplasms / pathology*
  • Salivary Gland Neoplasms / secondary
  • Salivary Gland Neoplasms / therapy